Riskpilot← Back to searchSign inGet full accessKEBOMED AS
ASActiveOrg 941668844Midtunhaugen 17, 5224 NesttunWholesale of pharmaceutical and medical goods · NACE 4646Est. 198627 employeeswww.kebomed.no
Revenue 2025
NOK 156,7M
+27% vs 2024
EBITDA margin
4.4%
-30% vs 2024
Equity ratio
46.4%
Financial strength
Net profit 2025
NOK 5,7M
-33% vs 2024
| Revenue | NOK 156,7M | +27% |
| EBITDA | NOK 6,9M | -30% |
| Net profit | NOK 5,7M | -33% |
| Total assets | NOK 74,7M | +6% |
| Equity | NOK 34,6M | +0% |
| Employees | 27 | — |
Legal name
KEBOMED AS
Org number
941668844
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
30. oktober 1986
Share capital
NOK 5 002 500
Employees
27 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Daglig leder og ett styremedlem i fellesskap.
Company purpose
Selskapets formål er handel og agentur og dertil tilhørende virksomhet.
Address
Midtunhaugen 17, 5224 Nesttun
Website
www.kebomed.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 38 562 | 36 875 | 35 594 | 35 425 | 28 817 | 59 262 | 71 789 | 82 615 | 83 322 | 82 435 | 78 939 | 84 601 | 87 209 | 103 473 | 97 938 | 106 171 | 123 402 | 156 677 |
| Staff expenses | −0 | −9 255 | −9 876 | −9 996 | −11 353 | −6 090 | −16 097 | −16 720 | −17 150 | −19 258 | −19 913 | −20 002 | −18 437 | −19 680 | −19 051 | −19 398 | −21 832 | −24 565 | −27 226 |
| EBITDA | 0 | −336 | −2 860 | 1 500 | −1 398 | −174 | 3 925 | 7 681 | 6 681 | 4 278 | 2 055 | −2 792 | 4 190 | 5 607 | 15 370 | 8 700 | 9 906 | 9 948 | 6 946 |
| Depreciation & amort. | −0 | −517 | −412 | −329 | −132 | −14 | −25 | −22 | −97 | −96 | −102 | −103 | −68 | −1 | −0 | −0 | −0 | −0 | −5 |
| EBIT | 0 | −853 | −3 272 | 1 171 | −1 531 | −188 | 3 900 | 7 659 | 6 584 | 4 181 | 1 953 | −2 896 | 4 122 | 5 606 | 15 370 | 8 700 | 9 906 | 9 948 | 6 940 |
| Net financials | 0 | −2 472 | 2 762 | 1 123 | 235 | 239 | −932 | −1 270 | −1 106 | 1 290 | −540 | −248 | −274 | −2 405 | 473 | −263 | −1 571 | 874 | 571 |
| Profit before tax | 0 | −3 325 | −510 | 2 294 | −1 296 | 51 | 2 968 | 6 390 | 5 478 | 5 471 | 1 413 | −3 144 | 3 848 | 3 201 | 15 843 | 8 437 | 8 335 | 10 822 | 7 511 |
| Tax | −0 | −0 | −604 | −0 | −0 | −0 | 779 | 1 577 | 1 786 | 1 412 | 1 008 | −0 | 580 | 1 287 | 2 401 | 2 004 | 1 604 | 2 348 | 1 817 |
| Net profit | 0 | −3 325 | 94 | 2 294 | −1 296 | 51 | 2 189 | 4 813 | 3 692 | 4 059 | 405 | −3 144 | 3 268 | 1 914 | 13 442 | 6 433 | 6 732 | 8 474 | 5 694 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | 19 062 | 15 874 | 19 479 | 22 587 | 21 072 | 23 538 | 31 858 | 28 722 | 33 885 | 33 508 | 31 472 | 36 994 | 32 085 | 43 803 | 44 384 | 59 233 | 70 519 | 74 680 |
| Equity | — | −3 344 | 350 | 2 644 | 5 348 | 5 399 | 7 588 | 9 900 | 9 900 | 9 959 | 10 365 | 7 221 | 10 489 | 12 403 | 12 985 | 19 418 | 26 150 | 34 623 | 34 623 |
| Long-term debt | 0 | 190 | 2 800 | 4 584 | −694 | −694 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 21 879 | 12 302 | 11 660 | 12 561 | 14 980 | 15 173 | 20 735 | 17 545 | 22 620 | 21 901 | 23 055 | 25 356 | 18 533 | 29 742 | 24 427 | 33 084 | 35 896 | 40 056 |
| Total debt | 0 | 22 069 | 15 102 | 16 244 | 16 545 | 14 980 | 15 173 | 20 735 | 17 545 | 22 620 | 21 901 | 23 055 | 25 356 | 18 533 | 29 742 | 24 427 | 33 084 | 35 896 | 40 056 |
EBITDA margin
4.4%
This company
15.8%
Market median
-72% vs market
20072025
Equity ratio
46.4%
This company
38.2%
Market median
+21% vs market
20072025
Return on equity
16.4%
This company
18.4%
Market median
+11% vs market
20072025
Net profit margin
3.6%
This company
8.1%
Market median
-56% vs market
20072025
Asset turnover
2.10×
This company
1.12×
Market median
+87% vs market
20072025
Debt / equity
1.16×
This company
0.62×
Market median
-87% vs market
20072025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-06-30
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BI Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Kebomed Europa Holding Ag | Company | 100.0% | 100.0% | 2024 |
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KEBOMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bjarte Ivan Olsen | Chief Executive Officer | 0 companies |
| Lars Løgstrup Poulsen | Chairman | 0 companies |
| Henrik Schjødt | Board of Directors | 0 companies |
| Søren Dalmark Kornerup | Board of Directors | 0 companies |